Genzyme's Wyntek Buy To Accelerate Point-Of-Care Stroke Test R&D
This article was originally published in The Gray Sheet
Executive Summary
Genzyme General's $65 mil. cash acquisition of rapid point-of-care test developer Wyntek Diagnostics will broaden Genzyme's existing rapid test portfolio and accelerate development of a quantitative rapid stroke panel, Genzyme says. Announced May 8, the deal is expected to close by July 1.
You may also be interested in...
PoC Test R&D Complicated By Emergency Consent Provisions – Genzyme Rep
FDA emergency research regulations requiring a therapeutic window to obtain informed consent may slow down development of rapid diagnostics for stroke and heart attack, according to Genzyme VP-Regulatory Affairs Robert Yocher
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.